Exact Sciences Corp. has entered into an agreement to buy Thrive Earlier Detection Corp. for cash and stock consideration of up to $2.15 billion in a move to strengthen its position in the emerging multi-cancer screening market.
Exact, the company behind the Cologuard stool-based colorectal cancer test has been upfront about its aspirations to be leader in...